Search

Your search keyword '"Bajel, A."' showing total 780 results
Start Over Author "Bajel, A."
780 results on '"Bajel, A."'

1. How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?

Author

Tiong, Ing Soo, Wall, Meaghan, Bajel, Ashish, Kalro, Akash, Fleming, Shaun, Roberts, Andrew W., Thiagarajah, Nisha, Chua, Chong Chyn, Latimer, Maya, Yeung, David, Marlton, Paula, Johnston, Amanda, Enjeti, Anoop, Fong, Chun Yew, Cull, Gavin, Larsen, Stephen, Kennedy, Glen, Schwarer, Anthony, Kipp, David, Ramanathan, Sundra, Verner, Emma, Tiley, Campbell, Morris, Edward, Hahn, Uwe, Moore, John, Taper, John, Purtill, Duncan, Warburton, Pauline, Stevenson, William, Murphy, Nicholas, Tan, Peter, Beligaswatte, Ashanka, Mutsando, Howard, Hertzberg, Mark, Shortt, Jake, Szabo, Ferenc, Dunne, Karin, and Wei, Andrew H.

Published
2024
Full Text
View/download PDF

2. How comparable are patient outcomes in the 'real-world' with populations studied in pivotal AML trials?

Author

Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, Andrew W. Roberts, Nisha Thiagarajah, Chong Chyn Chua, Maya Latimer, David Yeung, Paula Marlton, Amanda Johnston, Anoop Enjeti, Chun Yew Fong, Gavin Cull, Stephen Larsen, Glen Kennedy, Anthony Schwarer, David Kipp, Sundra Ramanathan, Emma Verner, Campbell Tiley, Edward Morris, Uwe Hahn, John Moore, John Taper, Duncan Purtill, Pauline Warburton, William Stevenson, Nicholas Murphy, Peter Tan, Ashanka Beligaswatte, Howard Mutsando, Mark Hertzberg, Jake Shortt, Ferenc Szabo, Karin Dunne, Andrew H. Wei, and Australasian Leukaemia and Lymphoma Group (ALLG)

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome. Using data from 942 AML patients enrolled between 2012–2018, we assessed age and disease-matched control and interventional populations from published randomized trials that led to the registration of midostaurin, gemtuzumab ozogamicin, CPX-351, oral azacitidine, and venetoclax. Our analyses highlight important differences in real-world outcomes compared to clinical trial populations, including variations in anthracycline type, cytarabine intensity and scheduling during consolidation, and the frequency of allogeneic hematopoietic cell transplantation in first remission. Although real-world outcomes were comparable to some published studies, notable differences were apparent in others. If historical datasets were used to assess the impact of novel therapies, this work underscores the need to assess diverse datasets to enable geographic differences in treatment outcomes to be accounted for.

Published
2024
Full Text
View/download PDF

3. Evaluating the cost-effectiveness of [18F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients

Author

Michelle Tew, Abby P. Douglas, Jeff Szer, Ashish Bajel, Simon J. Harrison, Shio Yen Tio, Leon J. Worth, Rodney J. Hicks, David Ritchie, Monica A. Slavin, Karin A. Thursky, and Kim Dalziel

Subjects
Cost-effectiveness, Costing, Diagnostic imaging, Febrile neutropenia, Antimicrobial, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background A recent randomised trial demonstrated [18F]fluorodeoxyglucose positron-emission tomography in combination with low-dose CT (FDG-PET/CT), compared to standard of care computed tomography (CT) imaging, positively impacted antimicrobial management and outcomes of acute leukaemia and haematopoietic stem cell transplant recipients with persistent and recurrent neutropenic fever. We conducted an economic evaluation from a healthcare perspective alongside the clinical trial. Methods Unit costs in Australian dollars were applied to all resources used (antimicrobials, diagnostic tests, ICU and hospital bed days). Effectiveness was measured as number of patients with antimicrobial rationalisation, 6-month mortality and quality-adjusted life years (QALYs) derived from patient-reported trial-based health-related quality-of-life. Generalised linear models were used to analyse costs and outcomes. Incremental cost-effectiveness ratios (ICERs) for all outcomes and net monetary benefit (NMB) for QALYs were calculated. We performed bootstrapping with 1000 replications using the recycled predictions method. Results The adjusted healthcare costs were lower for FDG-PET/CT (mean $49,563; 95%CI 36,867, 65,133) compared to CT (mean $57,574; 95% CI 44,837, 73,347). The difference in QALYs between the two groups was small (0.001; 95% CI -0.001, 0.004). When simulated 1000 times, FDG-PET/CT was the dominant strategy as it was cheaper with better outcomes than the standard CT group in 74% of simulations. The estimated NMBs at willingness-to-pay thresholds of $50,000 and $100,000 per QALY were positive, thus FDG-PET/CT remained cost-effective at these thresholds. Conclusions FDG-PET/CT is cost effective when compared to CT for investigation of persistent/recurrent neutropenic fever in high-risk patients, providing further support for incorporation of FDG-PET/CT into clinical guidelines and funding. Trial registration This trial is registered with ClinicalTrials.gov, NCT03429387.

Published
2023
Full Text
View/download PDF

5. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

Author

Loo, Sun, Roberts, Andrew W., Anstee, Natasha S., Kennedy, Glen A., He, Simon, Schwarer, Anthony P., Enjeti, Anoop K., D’Rozario, James, Marlton, Paula, Bilmon, Ian A., Taper, John, Cull, Gavin, Tiley, Campbell, Verner, Emma, Hahn, Uwe, Hiwase, Devendra K., Iland, Harry J., Murphy, Nick, Ramanathan, Sundra, Reynolds, John, Ong, Doen Ming, Tiong, Ing Soo, Wall, Meaghan, Murray, Michael, Rawling, Tristan, Leadbetter, Joanna, Rowley, Leesa, Latimer, Maya, Yuen, Sam, Ting, Stephen B., Fong, Chun Yew, Morris, Kirk, Bajel, Ashish, Seymour, John F., Levis, Mark J., and Wei, Andrew H.

Published
2023
Full Text
View/download PDF

6. The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry

Author

Fox, Lucy C., McQuilten, Zoe K., Firkin, Frank, Fox, Vanessa, Badoux, Xavier, Bajel, Ashish, Barbaro, Pasquale, Cole-Sinclair, Merrole F., Forsyth, Cecily, Gibson, John, Hiwase, Devendra K., Johnston, Anna, Mills, Anthony, Roncolato, Fernando, Sutherland, Robyn, Szer, Jeff, Ting, Stephen B., Vilcassim, Shahla, Young, Lauren, Waters, Neil A., and Wood, Erica M.

Published
2023
Full Text
View/download PDF

9. P365: SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA – FINAL RESULTS OF THE ALLG ALL08 STUDY

Author

Shaun Fleming, John Reynolds, Ashish Bajel, Nicola Venn, John Kwan, John Moore, David Yeung, Nalini Pati, Michael Leahy, Sushma Kollipara, Emma Verner, Leanne Berkahn, Rosemary Sutton, Andrew Wei, and Matthew Greenwood

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

10. P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)

Author

Armin Ghobadi, Ibrahim Aldoss, Shannon Maude, Alan S Wayne, Deepa Bhojwani, Ashish Bajel, Bhagirathbhai Dholaria, Rawan Faramand, Ryan Mattison, Michael Rettig, Ouiam Bakkacha, John Muth, Angela Pannunzio, Brett Ramsey, Eileen Mcnulty, Matthew Cooper, Jan Davidson-Moncada, Kenneth Jacobs, and John Dipersio

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

11. P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA

Author

Anthony Selwyn Stein, Mojca Jongen-Lavrencic, Sylvain Garciaz, Gerwin A Huls, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Shaun Fleming, C. Michel Zwaan, David C. de Leeuw, Pinkal Desai, Martha Lucia Arellano, David Avigan, Saskia Langemeijer, Kyle Jensen, Timothy Wagenaar, Gu MI, Giovanni Abbadessa, and Ashish Bajel

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

12. P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

Author

Giovanni Marconi, Shukaib Arslan, Shaun Fleming, Antonio Curti, James S Blachly, Giovanni Martinelli, Matteo Giovanni Della Porta, Ashish Bajel, Tim Sauer, Martina Crysandt, Arnaud Pigneux, Marina Konopleva, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Emily Rowe, Patricia Cheung, Ekaterina Jahn, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, and Nitin Jain

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

14. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Author

Rashidi, Armin, Hamadani, Mehdi, Zhang, Mei-Jie, Wang, Hai-Lin, Abdel-Azim, Hisham, Aljurf, Mahmoud, Assal, Amer, Bajel, Ashish, Bashey, Asad, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Bolaños-Meade, Javier, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Ciurea, Stefan, Copelan, Edward, Cutler, Corey, Daly, Andrew, Diaz, Miguel-Angel, Farhadfar, Nosha, Gale, Robert, Ganguly, Siddhartha, Grunwald, Michael, Hahn, Theresa, Hashmi, Shahrukh, Hildebrandt, Gerhard, Holland, H, Hossain, Nasheed, Kanakry, Christopher, Kharfan-Dabaja, Mohamed, Khera, Nandita, Koc, Yener, Lazarus, Hillard, Lee, Jong-Wook, Maertens, Johan, Martino, Rodrigo, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Palmisiano, Neil, Patel, Sagar, Pidala, Joseph, Olin, Rebecca, Olsson, Richard, Oran, Betul, Ringden, Olov, Rizzieri, David, Rowe, Jacob, Savoie, Mary, Schultz, Kirk, Seo, Sachiko, Shaffer, Brian, Singh, Anurag, Solh, Melhem, Stockerl-Goldstein, Keith, Verdonck, Leo, Wagner, John, Waller, Edmund, De Lima, Marcos, Sandmaier, Brenda, Litzow, Mark, Weisdorf, Dan, Romee, Rizwan, and Saber, Wael

Subjects
Adolescent, Adult, Aged, Blood Donors, Bone Marrow Transplantation, Calcineurin Inhibitors, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Leukemia, Myeloid, Acute, Male, Middle Aged, Recurrence, Remission Induction, Retrospective Studies, Siblings, Survival Analysis, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

Published
2019

15. [18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Douglas, Abby, Thursky, Karin, Spelman, Timothy, Szer, Jeff, Bajel, Ashish, Harrison, Simon, Tio, Shio Yen, Bupha-Intr, Olivia, Tew, Michelle, Worth, Leon, Teh, Benjamin, Chee, Lynette, Ng, Ashley, Carney, Dennis, Khot, Amit, Haeusler, Gabrielle, Yong, Michelle, Trubiano, Jason, Chen, Sharon, Hicks, Rodney, Ritchie, David, and Slavin, Monica

Published
2022
Full Text
View/download PDF

16. ANZTCT practice statement: sinusoidal obstruction syndrome/veno‐occlusive disease diagnosis and management.

Author

Fleming, Shaun, Scott, Ashleigh P., Coutsouvelis, John, Fraser, Chris, Bajel, Ashish, Nelson, Adam, Conyers, Rachel, McEwan, Ashley, Yeung, David, Campion, Victoria, Teague, Lochie, McGuire, Matthew, Morris, Edward, Gabriel, Melissa, Wayte, Rebecca, Douglas, Genevieve, Chien, Nicole, and Hamad, Nada

Subjects
LUNG disease diagnosis, LUNG disease prevention, THERAPEUTIC use of monoclonal antibodies, MEDICAL protocols, HEMATOPOIETIC stem cell transplantation, BLOOD, DISEASE management, PEDIATRICS, LUNG diseases, HEPATIC veno-occlusive disease, BONE marrow transplantation
Abstract

Sinusoidal obstruction syndrome/veno‐occlusive disease (SOS/VOD) is a life‐threatening complication which can develop after haemopoietic stem cell transplantation (HSCT) and some antibody–drug conjugates. Several SOS/VOD diagnostic and management guidelines exist, with the most recent and refined being the European Society for Blood and Marrow Transplantation adult and paediatric guidelines. Timely diagnosis and effective management (including the availability of therapeutic options) significantly contribute to improved patient outcomes. In Australia and New Zealand, there is variability in clinical practice and access to SOS/VOD therapies. This review aims to summarise the current evidence for SOS/VOD diagnosis, prevention and treatment and to provide recommendations for SOS/VOD in the context of contemporary Australasian HSCT clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Preneutropenic Fever in Patients With Hematological Malignancies: A Novel Target for Antimicrobial Stewardship.

Author

Chiodo-Reidy, Jessica, Slavin, Monica A, Tio, Shio Yen, Ng, Gywneth, Bajel, Ashish, Thursky, Karin A, and Douglas, Abby P

Subjects
BONE marrow transplantation, ACUTE myeloid leukemia, HEMATOLOGIC malignancies, ANTIMICROBIAL stewardship, NEUTROPENIA
Abstract

Background Many patients with hematological malignancy develop fever after chemotherapy/conditioning but before chemotherapy-induced neutropenia (preneutropenic fever [PNF]). The proportion of PNF with an infectious etiology is not well established. Methods We conducted a single-center, prospective observational substudy of PNF (neutrophils >0.5 cells/μL, ≥38.0°C) in adults receiving acute myeloid leukemia (AML) chemotherapy, or allogeneic hematopoietic cell transplant (allo-HCT) conditioning enrolled in a neutropenic fever randomized controlled trial between 1 January and 31 October 2018. Eligible patients had anticipated neutropenia ≥10 days and exclusions included concurrent infection and/or neutropenia prior to chemotherapy or conditioning. PNF rates and infections encountered were described. Associations between noninfectious etiologies and fever were explored. Antimicrobial therapy prescription across preneutropenic and neutropenic periods was examined. Results Of 62 consecutive patients included (43 allo-HCT, 19 AML), 27 had PNF (44%) and 5 (19%) had an infective cause. Among allo-HCT, PNF occurred in 14 of 17 (82%) who received thymoglobulin; only 1 of 14 (7%) had infection. During AML chemotherapy, 18 of 19 received cytarabine, of which 8 of 18 (44%) had PNF and 3 of 8 (38%) had infection. Most patients with PNF had antimicrobial therapy continued into the neutropenic period (19/27 [70%]). Those with PNF were more likely to be escalated to broader antimicrobial therapy at onset/during neutropenic fever (5/24 [21%] vs 2/30 [7%]). Conclusions Rates of PNF were high, and documented infection low, leading to prolonged and escalating antimicrobial therapy. In the absence of infection, early cessation of empiric therapy after PNF is recommended as an important stewardship intervention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)

Author

Tiong, Ing Soo, primary, Hiwase, Devendra K., additional, Abro, Emad, additional, Bajel, Ashish, additional, Palfreyman, Emma, additional, Beligaswatte, Ashanka, additional, Reynolds, John, additional, Anstee, Natasha, additional, Nguyen, Tamia, additional, Loo, Sun, additional, Chua, Chong Chyn, additional, Ashby, Michael, additional, Wiltshire, Kaitlyn M., additional, Fleming, Shaun, additional, Fong, Chun Y., additional, Teh, Tse-Chieh, additional, Blombery, Piers, additional, Dillon, Richard, additional, Ivey, Adam, additional, and Wei, Andrew H., additional

Published
2024
Full Text
View/download PDF

20. Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies

Author

Abadir, Edward, primary, Othman, Jad, additional, Kwan, John, additional, Gottlieb, David J., additional, Kennedy, Glen A., additional, Bajel, Ashish, additional, Doocey, Richard, additional, Perera, Travis, additional, Watson, Anne-Marie, additional, Bardy, Peter G., additional, Greenwood, Matthew, additional, Curtis, David J., additional, Tran, Steven, additional, Moore, John, additional, and Hamad, Nada, additional

Published
2024
Full Text
View/download PDF

22. ANZTCT practice statement: sinusoidal obstruction syndrome/veno-occlusive disease diagnosis and management.

Author

Fleming, S, Scott, AP, Coutsouvelis, J, Fraser, C, Bajel, A, Nelson, A, Conyers, R, McEwan, A, Yeung, D, Campion, V, Teague, L, McGuire, M, Morris, E, Gabriel, M, Wayte, R, Douglas, G, Chien, N, Hamad, N, Fleming, S, Scott, AP, Coutsouvelis, J, Fraser, C, Bajel, A, Nelson, A, Conyers, R, McEwan, A, Yeung, D, Campion, V, Teague, L, McGuire, M, Morris, E, Gabriel, M, Wayte, R, Douglas, G, Chien, N, and Hamad, N

Abstract

Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication which can develop after haemopoietic stem cell transplantation (HSCT) and some antibody-drug conjugates. Several SOS/VOD diagnostic and management guidelines exist, with the most recent and refined being the European Society for Blood and Marrow Transplantation adult and paediatric guidelines. Timely diagnosis and effective management (including the availability of therapeutic options) significantly contribute to improved patient outcomes. In Australia and New Zealand, there is variability in clinical practice and access to SOS/VOD therapies. This review aims to summarise the current evidence for SOS/VOD diagnosis, prevention and treatment and to provide recommendations for SOS/VOD in the context of contemporary Australasian HSCT clinical practice.

Published
2024

24. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Author

Zhou, Zheng, Nath, Rajneesh, Cerny, Jan, Wang, Hai-Lin, Zhang, Mei-Jie, Abdel-Azim, Hisham, Agrawal, Vaibhav, Ahmed, Gulrayz, Al-Homsi, A. Samer, Aljurf, Mahmoud, Alkhateeb, Hassan B., Assal, Amer, Bacher, Ulrike, Bajel, Ashish, Bashir, Qaiser, Battiwalla, Minocher, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Choe, Hannah, Copelan, Edward, Cutler, Corey, Damlaj, Moussab B., DeFilipp, Zachariah, De Lima, Marcos, Diaz, Miguel Angel, Farhadfar, Nosha, Foran, James, Freytes, César O., Gerds, Aaron T., Gergis, Usama, Grunwald, Michael R., Gul, Zartash, Hamadani, Mehdi, Hashmi, Shahrukh, Hertzberg, Mark, Hildebrandt, Gerhard C., Hossain, Nasheed, Inamoto, Yoshihiro, Isola, Luis, Jain, Tania, Kamble, Rammurti T., Khan, Muhammad Waqas, Kharfan-Dabaja, Mohamed A., Kebriaei, Partow, Kekre, Natasha, Khera, Nandita, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Liu, Hongtao, Marks, David I., Martino, Rodrigo, Mathews, Vikram, Mishra, Asmita, Murthy, Hemant S., Nagler, Arnon, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar S., Patnaik, Mrinal M., Pawarode, Attaphol, Perales, Miguel-Angel, Politikos, Ioannis, Popat, Uday, Rizzieri, David, Sandmaier, Brenda M., Savani, Bipin N., Seo, Sachiko, Shah, Nirav N., Uy, Geoffrey L., Valcárcel, David, Verdonck, Leo F., Waller, Edmund K., Wang, Youjin, Weisdorf, Daniel, Wirk, Baldeep, Wong, Eric, Yared, Jean A., and Saber, Wael

Published
2020
Full Text
View/download PDF

25. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Author

DeFilipp, Zachariah, Ancheta, Richard, Liu, Ying, Hu, Zhen-Huan, Gale, Robert Peter, Snyder, David, Schouten, Harry C., Kalaycio, Matt, Hildebrandt, Gerhard C., Ustun, Celalettin, Daly, Andrew, Ganguly, Siddhartha, Inamoto, Yoshihiro, Litzow, Mark, Szer, Jeffrey, Savoie, Mary Lynn, Hossain, Nasheed, Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, Reshef, Ran, Bajel, Ashish, Schultz, Kirk R., Gadalla, Shahinaz, Gerds, Aaron, Liesveld, Jane, Juckett, Mark B., Kamble, Rammurti, Hashmi, Shahrukh, Abdel-Azim, Hisham, Solh, Melhem, Bacher, Ulrike, Lazarus, Hillard, Olsson, Richard, Cahn, Jean-Yves, Grunwald, Michael R., Savani, Bipin N., Yared, Jean, Rowe, Jacob M., Cerny, Jan, Chaudhri, Naeem A., Aljurf, Mahmoud, Beitinjaneh, Amer, Seo, Sachiko, Nishihori, Taiga, Hsu, Jack W., Ramanathan, Muthalagu, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, and Saber, Wael

Published
2020
Full Text
View/download PDF

26. Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Author

Ghobadi, Armin, primary, Aldoss, Ibrahim, additional, Maude, Shannon L., additional, Bhojwani, Deepa, additional, Wayne, Alan S., additional, Bajel, Ashish, additional, Bhagirathbhai, Dr. Dholaria, additional, Faramand, Rawan G, additional, Mattison, Ryan J., additional, Rettig, Michael P., additional, Jacobs, Kenneth, additional, Bakkacha, Ouiam, additional, Muth, John, additional, Pannunzio, Angela, additional, Ramsey, Brett, additional, McNulty, Eileen, additional, Cooper, Matthew, additional, Davidson-Moncada, Jan, additional, and DiPersio, John F., additional

Published
2024
Full Text
View/download PDF

27. Clonal Architecture of Donor-Derived Myeloid Neoplasms after Allogeneic Hematopoietic Stem Cell Transplant

Author

Wechalekar, Gauri, primary, Cibich, Ms. Alia, additional, Shanmuganathan, Naranie, additional, Kutyna, Monika, additional, Sekaran, Usha Chandra, additional, Singhal, Deepak, additional, Beligaswatte, Ashanka, additional, Purins, Leanne, additional, Hahn, Christopher Norman, additional, Yeung, David T, additional, Bardy, Peter, additional, Purtill, Duncan, additional, Bajel, Ashish, additional, Branford, Susan, additional, and Hiwase, Devendra, additional

Published
2024
Full Text
View/download PDF

28. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.

Author

Thompson, Philip, Perera, Travis, Marin, David, Oran, Betul, Popat, Uday, Qazilbash, Muzaffar, Shah, Nina, Parmar, Simrit, Rezvani, Katayoun, Olson, Amanda, Kebriaei, Partow, Anderlini, Paolo, Rondon, Gabriela, Alousi, Amin, Ciurea, Stefan, Champlin, Richard, Bajel, Ashish, Szer, Jeffrey, Shpall, Elizabeth, Ritchie, David, and Hosing, Chitra

Subjects
Clinical results, graft-versus-host disease, lymphoma and Hodgkin disease, Adolescent, Adult, Combined Modality Therapy, Cord Blood Stem Cell Transplantation, Drug Resistance, Neoplasm, Female, Graft vs Host Disease, Hodgkin Disease, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Retreatment, Transplantation Conditioning, Treatment Outcome, Young Adult
Abstract

A sub-group of patients with Hodgkin Lymphoma (HL) who relapse after autologous stem cell transplant can achieve long-term disease-free-survival after allogeneic stem cell transplant (alloSCT). There is limited information regarding the tolerability and efficacy of double umbilical cord blood transplant (dUCBT) for relapsed/refractory HL. We analyzed 27 consecutive, heavily pre-treated patients receiving dUCBT for relapsed/refractory HL at two centers from 2003-2014. The majority of patients relapsed

Published
2016

29. OP122 Economic Evidence To Support Expanding Use Of Existing Positron Emission Tomography Technology As A Diagnostic Tool For High-Risk Cancer Patients

Author

Tew, Michelle, primary, Douglas, Abby, additional, Szer, Jeff, additional, Bajel, Ashish, additional, Harrison, Simon, additional, Tio, Shio Yen, additional, Worth, Leon, additional, Hicks, Rodney, additional, Ritchie, David, additional, Slavin, Monica, additional, Thursky, Karin, additional, and Dalziel, Kim, additional

Published
2023
Full Text
View/download PDF

30. Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting

Author

Ouli Xie, Monica A. Slavin, Benjamin W. Teh, Ashish Bajel, Abby P. Douglas, and Leon J. Worth

Subjects
Vancomycin-resistant enterococci, Bacteremia, Leukemia, Teicoplanin, Linezolid, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Vancomycin-resistant enterococcus (VRE) is an important cause of infection in immunocompromised populations. Few studies have described the characteristics of vanB VRE infection. We sought to describe the epidemiology, treatment and outcomes of VRE bloodstream infections (BSI) in a vanB predominant setting in malignant hematology and oncology patients. Methods A retrospective review was performed at two large Australian centres and spanning a 6-year period (2008–2014). Evaluable outcomes were intensive care admission (ICU) within 48 h of BSI, all-cause mortality (7 and 30 days) and length of admission. Results Overall, 106 BSI episodes were observed in 96 patients, predominantly Enterococcus faecium vanB (105/106, 99%). Antibiotics were administered for a median of 17 days prior to BSI, and 76/96 (79%) were neutropenic at BSI onset. Of patients screened before BSI onset, 49/72 (68%) were found to be colonised. Treatment included teicoplanin (59), linezolid (6), daptomycin (2) and sequential/multiple agents (21). Mortality at 30-days was 31%. On multivariable analysis, teicoplanin was not associated with mortality at 30 days. Conclusions VRE BSI in a vanB endemic setting occurred in the context of substantive prior antibiotic use and was associated with high 30-day mortality. Targeted screening identified 68% to be colonised prior to BSI. Teicoplanin therapy was not associated with poorer outcomes and warrants further study for vanB VRE BSI in cancer populations.

Published
2020
Full Text
View/download PDF

33. ANZTCT consensus position statement on ruxolitinib in steroid‐refractory acute and chronic graft‐versus‐host disease

Author

Hamad, Nada, primary, Bilmon, Ian, additional, Chee, Lynette, additional, Henden, Andrea, additional, Johnston, Anna, additional, Purtill, Duncan, additional, Bajel, Ashish, additional, Tey, Siok‐Keen, additional, Yeung, David, additional, Cole, Theresa, additional, Lewis, Clinton, additional, and Butler, Jason, additional

Published
2023
Full Text
View/download PDF

34. If we do not count it, it does not count: ethnicity in allogeneic haemopoietic stem cell transplant in Australia

Author

McErlean, Gemma, primary, Bajel, Ashish, additional, Bhattacharyya, Abir, additional, Brown, Ngaire, additional, De Abreu Lourenco, Richard, additional, Greenwood, Matthew, additional, Kerridge, Ian, additional, Kim, Nancy, additional, Kliman, David, additional, Maneze, Della, additional, O'Brien, Tracey, additional, Szer, Jeff, additional, and Twist, Ida, additional

Published
2023
Full Text
View/download PDF

39. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Author

Radivoyevitch, Tomas, Dean, Robert M., Shaw, Bronwen E., Brazauskas, Ruta, Tecca, Heather R., Molenaar, Remco J., Battiwalla, Minoo, Savani, Bipin N., Flowers, Mary E.D., Cooke, Kenneth R., Hamilton, Betty K., Kalaycio, Matt, Maciejewski, Jaroslaw P., Ahmed, Ibrahim, Akpek, Görgün, Bajel, Ashish, Buchbinder, David, Cahn, Jean-Yves, D’Souza, Anita, Daly, Andrew, DeFilipp, Zachariah, Ganguly, Siddhartha, Hamadani, Mehdi, Hayashi, Robert J., Hematti, Peiman, Inamoto, Yoshihiro, Khera, Nandita, Kindwall-Keller, Tamila, Landau, Heather, Lazarus, Hillard, Majhail, Navneet S., Marks, David I., Olsson, Richard F., Seo, Sachiko, Steinberg, Amir, William, Basem M., Wirk, Baldeep, Yared, Jean A., Aljurf, Mahmoud, Abidi, Muneer H., Allewelt, Heather, Beitinjaneh, Amer, Cook, Rachel, Cornell, Robert F., Fay, Joseph W., Hale, Gregory, Chakrabarty, Jennifer Holter, Jodele, Sonata, Kasow, Kimberly A., Mahindra, Anuj, Malone, Adriana K., Popat, Uday, Rizzo, J. Douglas, Schouten, Harry C., Warwick, Anne B., Wood, William A., Sekeres, Mikkael A., Litzow, Mark R., Gale, Robert P., and Hashmi, Shahrukh K.

Published
2018
Full Text
View/download PDF

40. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Author

Sanders, Mathijs A., Chew, Edward, Flensburg, Christoffer, Zeilemaker, Annelieke, Miller, Sarah E., al Hinai, Adil S., Bajel, Ashish, Luiken, Bram, Rijken, Melissa, Mclennan, Tamara, Hoogenboezem, Remco M., Kavelaars, François G., Fröhling, Stefan, Blewitt, Marnie E., Bindels, Eric M., Alexander, Warren S., Löwenberg, Bob, Roberts, Andrew W., Valk, Peter J.M., and Majewski, Ian J.

Published
2018
Full Text
View/download PDF

41. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Hogan, William, Battiwalla, Minoo, Copelan, Edward, Hildebrandt, Gerhard, Ganguly, Sid, Majhail, Navneet, Woolfrey, Ann, Nivison-Smith, Ian, Hertzberg, Mark, Diaz, Miguel Angel, Jakubowski, Ann, Ustun, Celalettin, Yong, Agnes, Freytes, Cesar, DeFilipp, Zachariah, Inamoto, Yoshi, Cahn, Jean-Yves, Savani, Bipin, Yared, Jean, Bajel, Ashish, Bacher, Ulrike, Uy, Geoffrey, Rizzieri, David, Wieduwilt, Matthew, Schultz, Kirk, Grunwald, Michael, Kamble, Rammurti, Qayed, Muna, Brammer, Jonathan, Ballen, Karen, Khera, Nandita, Schouten, Harry, Bierings, Marc, Kanakry, Christopher, Wood, William Allen, Saad, Ayman, Savoie, Lynn, Hamilton, Betty Ky, Aljurf, Mahmoud, Vij, Ravi, Pawarode, Attaphol, Olsson, Richard, Wirk, B. Mona, Beitinjaneh, Amer, Seo, Sachiko, Cerny, Jan, Akpek, Gorgun, Norkin, Maxim, Nishihori, Taiga, Lazaryan, Aleksandr, Sabloff, Mitchell, Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H. Jean, Sandmaier, Brenda M., Horowitz, Mary M., Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard M., Gale, Robert Peter, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew D., Pulsipher, Michael A., Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David I.

Published
2018
Full Text
View/download PDF

43. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: <scp>COVID</scp> ‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell

Author

Jacinta Perram, Duncan Purtill, Ashish Bajel, Jason Butler, Tracey O'Brien, Benjamin Teh, Nicole Gilroy, Phoebe J. Ho, Richard Doocey, Thomas Hills, Travis Perera, Genevieve Douglas, Shanti Ramachandran, Lynette Chee, Judith Trotman, Robert Weinkove, Steven Keogh, Chris Fraser, Tara Cochrane, Anne‐Marie Watson, Peter Diamond, Maya Latimer, Ian Irving, Emily Blyth, Chan Cheah, Theresa Cole, Sam Milliken, Hung Yang, Matthew Greenwood, Peter Bardy, Glen Kennedy, Stephen Larsen, Rachel Conyers, and Nada Hamad

Subjects
Internal Medicine
Published
2023

45. P365: SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA – FINAL RESULTS OF THE ALLG ALL08 STUDY

Author

Fleming, Shaun, primary, Reynolds, John, additional, Bajel, Ashish, additional, Venn, Nicola, additional, Kwan, John, additional, Moore, John, additional, Yeung, David, additional, Pati, Nalini, additional, Leahy, Michael, additional, Kollipara, Sushma, additional, Verner, Emma, additional, Berkahn, Leanne, additional, Sutton, Rosemary, additional, Wei, Andrew, additional, and Greenwood, Matthew, additional

Published
2023
Full Text
View/download PDF

46. P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR443579 IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH RISK-MYELODYSPLASIA

Author

Selwyn Stein, Anthony, primary, Jongen-Lavrencic, Mojca, additional, Garciaz, Sylvain, additional, A Huls, Gerwin, additional, Maiti, Abhishek, additional, Boissel, Nicolas, additional, De Botton, Stephane, additional, Fleming, Shaun, additional, Michel Zwaan, C., additional, C. de Leeuw, David, additional, Desai, Pinkal, additional, Lucia Arellano, Martha, additional, Avigan, David, additional, Langemeijer, Saskia, additional, Jensen, Kyle, additional, Wagenaar, Timothy, additional, MI, Gu, additional, Abbadessa, Giovanni, additional, and Bajel, Ashish, additional

Published
2023
Full Text
View/download PDF

48. P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)

Author

Ghobadi, Armin, primary, Aldoss, Ibrahim, additional, Maude, Shannon, additional, S Wayne, Alan, additional, Bhojwani, Deepa, additional, Bajel, Ashish, additional, Dholaria, Bhagirathbhai, additional, Faramand, Rawan, additional, Mattison, Ryan, additional, Rettig, Michael, additional, Bakkacha, Ouiam, additional, Muth, John, additional, Pannunzio, Angela, additional, Ramsey, Brett, additional, Mcnulty, Eileen, additional, Cooper, Matthew, additional, Davidson-Moncada, Jan, additional, Jacobs, Kenneth, additional, and Dipersio, John, additional

Published
2023
Full Text
View/download PDF

49. P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

Author

Marconi, Giovanni, primary, Arslan, Shukaib, additional, Fleming, Shaun, additional, Curti, Antonio, additional, S Blachly, James, additional, Martinelli, Giovanni, additional, Giovanni Della Porta, Matteo, additional, Bajel, Ashish, additional, Sauer, Tim, additional, Crysandt, Martina, additional, Pigneux, Arnaud, additional, Konopleva, Marina, additional, Marmor, Yotvat, additional, Sharma, Shringi, additional, Elgeioushi, Nairouz, additional, Rowe, Emily, additional, Cheung, Patricia, additional, Jahn, Ekaterina, additional, Saeh, Jamal, additional, Tibes, Raoul, additional, Zumla Cader, Fathima, additional, and Jain, Nitin, additional

Published
2023
Full Text
View/download PDF

50. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome

Author

Claire Palles, Hannah D. West, Edward Chew, Sara Galavotti, Christoffer Flensburg, Judith E. Grolleman, Erik A.M. Jansen, Helen Curley, Laura Chegwidden, Edward H. Arbe-Barnes, Nicola Lander, Rebekah Truscott, Judith Pagan, Ashish Bajel, Kitty Sherwood, Lynn Martin, Huw Thomas, Demetra Georgiou, Florentia Fostira, Yael Goldberg, David J. Adams, Simone A.M. van der Biezen, Michael Christie, Mark Clendenning, Laura E. Thomas, Constantinos Deltas, Aleksandar J. Dimovski, Dagmara Dymerska, Jan Lubinski, Khalid Mahmood, Rachel S. van der Post, Mathijs Sanders, Jürgen Weitz, Jenny C. Taylor, Clare Turnbull, Lilian Vreede, Tom van Wezel, Celina Whalley, Claudia Arnedo-Pac, Giulio Caravagna, William Cross, Daniel Chubb, Anna Frangou, Andreas J. Gruber, Ben Kinnersley, Boris Noyvert, David Church, Trevor Graham, Richard Houlston, Nuria Lopez-Bigas, Andrea Sottoriva, David Wedge, Mark A. Jenkins, Roland P. Kuiper, Andrew W. Roberts, Jeremy P. Cheadle, Marjolijn J.L. Ligtenberg, Nicoline Hoogerbrugge, Viktor H. Koelzer, Andres Dacal Rivas, Ingrid M. Winship, Clara Ruiz Ponte, Daniel D. Buchanan, Derek G. Power, Andrew Green, Ian P.M. Tomlinson, Julian R. Sampson, Ian J. Majewski, Richarda M. de Voer, Hematology, Palles, Claire, West, Hannah D, Chew, Edward, Galavotti, Sara, Flensburg, Christoffer, Grolleman, Judith E, Jansen, Erik A M, Curley, Helen, Chegwidden, Laura, Arbe-Barnes, Edward H, Lander, Nicola, Truscott, Rebekah, Pagan, Judith, Bajel, Ashish, Sherwood, Kitty, Martin, Lynn, Thomas, Huw, Georgiou, Demetra, Fostira, Florentia, Goldberg, Yael, Adams, David J, van der Biezen, Simone A M, Christie, Michael, Clendenning, Mark, Thomas, Laura E, Deltas, Constantino, Dimovski, Aleksandar J, Dymerska, Dagmara, Lubinski, Jan, Mahmood, Khalid, van der Post, Rachel S, Sanders, Mathij, Weitz, Jürgen, Taylor, Jenny C, Turnbull, Clare, Vreede, Lilian, van Wezel, Tom, Whalley, Celina, Arnedo-Pac, Claudia, Caravagna, Giulio, Cross, William, Chubb, Daniel, Frangou, Anna, Gruber, Andreas J, Kinnersley, Ben, Noyvert, Bori, Church, David, Graham, Trevor, Houlston, Richard, Lopez-Bigas, Nuria, Sottoriva, Andrea, Wedge, David, Jenkins, Mark A, Kuiper, Roland P, Roberts, Andrew W, Cheadle, Jeremy P, Ligtenberg, Marjolijn J L, Hoogerbrugge, Nicoline, Koelzer, Viktor H, Rivas, Andres Dacal, Winship, Ingrid M, Ponte, Clara Ruiz, Buchanan, Daniel D, Power, Derek G, Green, Andrew, Tomlinson, Ian P M, Sampson, Julian R, Majewski, Ian J, and de Voer, Richarda M

Subjects
Uveal Neoplasms, Endodeoxyribonucleases, 5′-methylcytosine deamination, polyposis, colorectal cancer, Colorectal Neoplasm, mutational signature, Germ Cell, Endodeoxyribonuclease, Germ Cells, Adenomatous Polyposis Coli, ddc:570, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], mutator phenotype, Genetics, Humans, Genetic Predisposition to Disease, Germ-Line Mutation, Colorectal Neoplasms, polyposi, Genetics (clinical), Human
Abstract

Contains fulltext : 251996.pdf (Publisher’s version ) (Open Access) We report an autosomal recessive, multi-organ tumor predisposition syndrome, caused by bi-allelic loss-of-function germline variants in the base excision repair (BER) gene MBD4. We identified five individuals with bi-allelic MBD4 variants within four families and these individuals had a personal and/or family history of adenomatous colorectal polyposis, acute myeloid leukemia, and uveal melanoma. MBD4 encodes a glycosylase involved in repair of G:T mismatches resulting from deamination of 5'-methylcytosine. The colorectal adenomas from MBD4-deficient individuals showed a mutator phenotype attributable to mutational signature SBS1, consistent with the function of MBD4. MBD4-deficient polyps harbored somatic mutations in similar driver genes to sporadic colorectal tumors, although AMER1 mutations were more common and KRAS mutations less frequent. Our findings expand the role of BER deficiencies in tumor predisposition. Inclusion of MBD4 in genetic testing for polyposis and multi-tumor phenotypes is warranted to improve disease management.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results